Proximal Ventures raises debut fund to back startups bringing AI to drug development

Sahir Raoof has raised $27.5 million for his debut venture capital fund, Proximal Ventures, which focuses on startups using AI to streamline pharmaceutical drug development. The fund aims to capitalize on the potential for AI to automate service-heavy tasks in the life sciences industry.
Why it matters
This highlights the growing trend of specialized VC funds targeting the intersection of AI and healthcare to improve efficiency in drug discovery.
While established venture firms continue to attract capital, first-time fund managers are facing one of the toughest fundraising environments in years. But that didn’t stop Sahir Raoof, a former SignalFire investor and executive at two healthcare startups, from raising $27.5 million for his first solo VC fund.
Raoof’s firm, Proximal Ventures , is betting that AI can transform the tools, infrastructure, and services that support drug development.
Pharmaceutical companies have historically outsourced various stages of drug development to specialized service providers, from synthesizing thousands of molecular compounds and figuring out how to manufacture drugs at scale to analyzing clinical trial data.
“For a long time, the assumption was that pharma is not a great buyer of software, but a really good buyer of services,” Raoof told TechCrunch.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in